NOTE 12 - SEGMENT INFORMATION

12 Months Ended

Apr. 30, 2020

Notes

NOTE 12 - SEGMENT INFORMATION

NOTE 12 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for fiscal years ended April 30, 2020 and 2019; we operated in two reportable business segments - (1) natural sweetener (stevioside), (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Financial information with respect to these reportable business segments for the fiscal years ended April 30, 2020 and 2019 is as follows:

	Fiscal Years Ended April 30,
	2020	2019
Revenues:
Stevioside - third party	$17,019,948	$13,740,838
Stevioside - related party	8,218,993	4,421,864
Total Stevioside	25,238,941	18,162,702
Corporate and other – third party	852,543	2,687,743
Corporate and other – related party	0	0
Total Corporate and other	852,543	2,687,743
Total segment and consolidated revenues	$26,091,484	$20,850,445
Interest expense:
Stevioside	$(747,296)	$(804,060)
Corporate and other	0	0
Total segment and consolidated interest expense	$(747,296)	$(804,060)
Depreciation:
Stevioside	$1,026,820	$937,163
Corporate and other	191,767	156,669
Total segment and consolidated depreciation	$1,218,587	$1,093,832
Gain (loss) from continuing operations before income taxes:
Stevioside	$(1,398,749)	$(3,865,876)
Corporate and other	269,497	(798,082)
Total gain (loss) from continuing operations before income taxes	$(1,129,252)	$(4,663,958)

	April 30, 2020	April 30, 2019
Segment property and equipment:
Stevioside	$6,976,153	$7,796,314
Corporate and other	1,925,395	1,197,083
Total property and equipment	$8,901,548	$8,993,397